Merck Non-GAAP EPS of $2.49 beats by $0.40, revenue of $18.09B beats by $760M (MRK:NYSE)

Merck reported Q3 Non-GAAP EPS of $2.49, exceeding estimates by $0.40, with revenue of $18.09B, up 4.6% Y/Y and $760M above expectations. KEYTRUDA sales reached $8.6B, with $830M from KEYTRUDA QLEX. WINREVAIR sales were also reported.

Original reporting
Published Oct 29, 2026, 10:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MRK
Bullish
high confidence
Mentioned
$MRK
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$MRKBullishHigh
01

Why it matters

The beat on earnings and revenue is likely to trigger a short‑term rally.

02

Market read

First report of Merck's Q3 earnings beat; material for traders.

03

What to watch

Potential headwinds from generic competition and upcoming regulatory reviews.

Relevance 9/10Novelty 9/10Timing: post‑market today

Background

Merck's Q3 results were released via a press release on Oct 29, 2026.

Company-level read

Ticker impact

$MRKBullishHigh confidence
Context

Merck reported Q3 non‑GAAP EPS of $2.49, beating expectations by $0.40 and revenue of $18.09B, up $760M.

Expected impact

upward pressure as the market prices in the earnings beat

Evidence & confidence

Large‑cap pharma beat on both EPS and revenue typically lifts the stock in post‑market trading.

Market effects

Boosts broader pharma sector expectations for Q3 earnings.

Supports US healthcare index performance.

May influence global biotech sentiment as Merck is a benchmark name.

Counterpoint

Investors may question sustainability of growth given modest revenue expansion.

Key entities

  • Merck & Co.

    Global pharmaceutical company reporting Q3 results.

Related articles

$MRKHigh

Why Merck (MRK) Stock Is Down Today

Merck (MRK) shares fell 3.8% after the company discontinued the BELLWAVE clinical program for nemtabrutinib, citing potential risks outweighing benefits in a Phase 3 trial. The decision impacts multiple studies, marking a pipeline setback for the drugmaker. Merck's latest earnings report had shown revenue growth and pipeline activity before this development.

$MRKHigh

Merck wins all 14 U.S. patent reviews against Halozyme

Merck (MSD) won all 14 U.S. patent reviews against Halozyme, securing its Keytruda Qlex cancer immunotherapy's subcutaneous injection technology. The Patent Trial and Appeal Board ruled all challenged claims unpatentable. Keytruda Qlex sales reached $830M in Q3, 9.7% of total Keytruda sales. Halozyme may appeal, and a patent infringement lawsuit is ongoing.